Could the Road to an AKS Violation Be Paved with Good Intentions? Pfizer Asks SCOTUS
FDA Law Blog
NOVEMBER 6, 2022
Now, after an unfavorable HHS Office of the Inspector General (OIG) advisory opinion and two defeats in court, Pfizer has appealed the Second Circuit’s decision to the Supreme Court. The Second Circuit’s Interpretation of the AKS and its Mens Rea Element.
Let's personalize your content